arrow_back Back to App

Extended Protection for Innovative Gene-Targeted Drugs

This act extends the protection period for new, advanced gene-targeted drugs, potentially encouraging companies to invest in their development. For citizens, this could mean greater access to innovative therapies in the future, but also a longer wait before generic versions of these drugs become available.
Key points
The protection period for certain advanced gene-targeted drugs will be extended from 7 to 11 years.
This change applies to drugs using gene-targeting technologies that can modulate gene function.
The aim is to support research and development of new, groundbreaking gene therapies.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_1672
Sponsor: Rep. Davis, Donald G. [D-NC-1]
Process start date: 2025-02-27
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Maintaining Investments in New Innovation Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_1672.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-02-27.

What are the main provisions?

Key points include:

  • The protection period for certain advanced gene-targeted drugs will be extended from 7 to 11 years.
  • This change applies to drugs using gene-targeting technologies that can modulate gene function.
  • The aim is to support research and development of new, groundbreaking gene therapies.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Davis, Donald G. [D-NC-1].

What is the latest detailed status?

The latest detailed status is: Introduced in House

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

CATEGORIES

Health